c-Kit (T670I)

KIT · Variant type: point · HGVS: p.T670I

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Gilteritinib	97.8%	2.2%	88.97
2	Pacritinib	96.9%	3.1%	88.64
3	Selpercatinib	96.5%	3.5%	96.72
4	Ponatinib	95.7%	4.3%	78.23
5	Nintedanib	94.4%	5.6%	90.23
6	Erdafitinib	93.3%	6.7%	95.71
7	Pralsetinib	92.8%	7.2%	93.43
8	Axitinib	91.6%	8.4%	93.23
9	Cabozantinib	91.5%	8.5%	92.73
10	Avapritinib	89.9%	10.1%	97.73
11	Tivozanib	89.1%	10.9%	92.42
12	Sunitinib	86.3%	13.7%	91.73
13	Lenvatinib	83.0%	17.0%	97.74
14	Regorafenib	81.3%	18.7%	95.99
15	Pazopanib	77.2%	22.8%	97.49
16	Sorafenib	73.6%	26.4%	96.72
17	Fedratinib	68.4%	31.6%	96.21
18	Lazertinib	65.4%	34.6%	97.47
19	Entrectinib	62.8%	37.2%	93.69
20	Brigatinib	62.6%	37.4%	82.96
21	Nilotinib	59.6%	40.4%	96.49
22	Defactinib	58.8%	41.2%	92.68
23	Ripretinib	57.2%	42.8%	92.95
24	Crizotinib	55.9%	44.1%	91.39
25	Pemigatinib	48.1%	51.9%	98.23

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Gilteritinib	97.8%	—	—
Pacritinib	96.9%	—	—
Selpercatinib	96.5%	—	—
Ponatinib	95.7%	—	—
Nintedanib	94.4%	—	—
Erdafitinib	93.3%	—	—
Pralsetinib	92.8%	—	—
Axitinib	91.6%	—	—
Cabozantinib	91.5%	—	—
Avapritinib	89.9%	—	—
Tivozanib	89.1%	—	—
Sunitinib	86.3%	—	—
Lenvatinib	83.0%	—	—
Regorafenib	81.3%	—	—
Pazopanib	77.2%	—	—
Sorafenib	73.6%	—	—
Fedratinib	68.4%	—	—
Lazertinib	65.4%	—	—
Entrectinib	62.8%	—	—
Brigatinib	62.6%	—	—
Nilotinib	59.6%	—	—
Defactinib	58.8%	—	—
Ripretinib	57.2%	—	—
Crizotinib	55.9%	—	—
Pemigatinib	48.1%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 15.8ms